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Abstract
The self-controlled case series method is increasingly being used in pharmacoepidemiology,
particularly in vaccine safety studies. This method is typically used to evaluate the association
between a transient exposure and an acute event, using only cases. We present both para-
metric and semiparametric models using a motivating example on MMR vaccine and bleeding
disorders. We briefly describe approaches for censoring events and a sequential version of the
method for prospective surveillance of drug safety. The efficiency of the self-controlled case se-
ries method is compared to the that of cohort and case control studies. Some further extensions,
to long or indefinite exposures and to bivariate counts, are described.
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1 Introduction
The self-controlled case series method, or case series method for short, can be used to study the
temporal association between a time-varying exposure and an adverse event using data on cases
only. The key advantages are that it often has high efficiency relative to the cohort method and that
it is self-controlled: time-invariant confounders, such as sex, location, genetics, underlying state of
health are controlled for implicitly. This paper begins by introducing the model and likelihood,
with an example. Key assumptions, study design and model fitting are discussed.
When the method was first introduced in 1995, it was used to study the association between
vaccines and adverse events [1] [2]. It gained wider recognition after its use in a study of the
association between mumps, measles and rubella (MMR) vaccine and autism and since then has
grown steadily in its use [3]. In 2003 Hubbard et al. were the first to use the self-controlled case
series method for an exposure that was not a vaccine in a study of antidepressant use and the risk
of hip fracture [4].
More recently, the self-controlled case series method has been developed further. A semiparamet-
ric approach was proposed by Farrington and Whitaker to avoid mis-specification of the age-specific
baseline incidence [5]. This approach is described in Section 4. For events whose occurrence censors
the subsequent exposure, such as the occurrence of an adverse event which results in stopping the
treatment, the case series method can be adapted to allow for missing exposure data, as described
in Section 5. The case series method can also be adapted for use in prospective surveillance of drug
or vaccine safety using risk-adjusted SPRT, described in Section 6.
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2 Implementation of the case series method
2.1 Model and likelihood
The self-controlled case series method is based on data on cases only, but may be derived from
an underlying Poisson cohort model as follows. We begin with a cohort of individuals. For each
individual i in this cohort we define an observation period (ai, bi], over which data on event times and
exposure history are available. For each individual, events arise according to a non-homogeneous
Poisson process. Each individual’s observation period is split into age groups j. From the exposure
histories, risk periods k, k = 1, 2, ... are defined. Risk periods are windows of time either during or
after the exposure when individuals are deemed to be at increased (or reduced) risk of the event of
interest. Any other times within the observation period, that is before, after or between the risk
periods, constitute the control periods, indexed by k = 0.
Let nijk and eijk denote, respectively, the number of events experienced and the time spent by
individual i in age group j and risk period k. The incidence rate, denoted by λijk, is assumed to be
constant within each such interval and at any one time point is given by the following multiplicative
model:
λijk = exp(φi + αj + βk) (1)
where φi is an effect for individual i, αj is an effect for age group j, and βk is an effect for risk
period k. α0 = 0 and β0 = 0, so that the baseline incidence λi00 is exp(φi). The number of
events nijk occurring within an interval of length eijk is assumed to be Poisson with rate eijkλijk.
The exponentiated quantities exp(βk) are referred to as relative incidences and are a measure of
incidence in risk period k relative to the control period k = 0.
Assuming that the exposure is not influenced by prior events, we condition on the number of
events ni =
∑
j,k nijk observed for individual i during (ai, bi]. The kernel of the resulting conditional
likelihood is product multinomial. The contibution of an individual i is:
Li(α, β) =
∏
j,k
(
eijk exp(αj + βk)∑
r,s eirs exp(αr + βs)
)nijk
. (2)
Consequently, the individual effects φi cancel out, it is in this sense that the method is self-controlled:
these individual effects include any time-invariant confounders or random effects. Only age (or other
time-dependent covariates) need to be modelled, though it is possible to include the interactions
between time-invariant confounders and the exposure effect.
Individuals i with no events (ni = 0) in (ai, bi] contribute 1 to the conditional likelihood in
equation (2), and hence only cases within the underlying cohort, that is, individuals with ni ≥ 1,
need be sampled. Suppose that there are n such cases, re-indexed by i = 1, ..., n. The self-controlled
case series likelihood is then
L(α, β) =
n∏
i=1
∏
j,k
(
eijk exp(αj + βk)∑
r,s eirs exp(αr + βs)
)nijk
. (3)
Asymptotic and small sample properties of maximum likelihood estimates obtained from this con-
ditional likelihood are discussed in Musonda et al. [6], together with simulation inference methods.
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2.2 Motivating example: MMR vaccine and ITP
Idiopathic thrombocytopenic purpura (ITP) is a rare, potentially recurrent autoimmune disorder in
which abnormal bleeding into the skin occurs due to low blood platelet count. Miller et al. studied
the association between mumps, measles and rubella vaccine (MMR) and hospital admission for
ITP within the South East and North East Thames Regions in the UK [7]. ITP cases arising
during the period from October 1991 to September 1994 and aged 12-23 months were included in
the analysis. These time and age boundaries were used to define the observation period for each
case. The data set included a total of 44 admissions experienced by 35 children; 5 of these children
were admitted twice and 1 was admitted 5 times. Six age groups were used: 366-426, 427-487,
488-548, 549-609, 610-670 and 671-730 days of age. It was hypothesized that MMR vaccination
may, in rare instances, cause ITP. Risk periods covered the 6 week period after MMR vaccination,
and three two-week long risk periods 0-14, 15-28 and 29-42 days after vaccination were used. Of the
44 events, 13 occurred within 6 weeks after receipt of the MMR vaccine and 31 of the 35 children
were exposed between one and two years of age.
Figure 1 shows time lines of the observation period for the first three individuals i = 1, 2, 3
included in the data set. Observation periods ran from ages 454 to 730 days for individual 1 and
from ages 366 to 730 days for individuals 2 and 3. Vaccination times and risk periods are shown for
individuals 1 and 3, individual 2 was not vaccinated during his or her observation period. Individual
1 was admitted to hospital for ITP during the second post MMR risk period.
Figure 1: Observation periods for the first 3 individuals in the ITP and MMR data set.
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2.3 Fitting the case series model
The multinomial likelihood (3) can be fitted using most statistical software packages as an associated
Poisson regression model with log link function. Data need to be formatted with one line for each
interval, listing the number of events occurring within that interval nijk, the length of the interval
eijk and factors for age group j and risk group k; a factor for individual i is also included to ensure
that the fitted individual totals equal the observed values. The Poisson model has the number of
events nijk as the response variable and the log interval lengths ln(eijk) are included as an offset:
nijk ∼ Poisson(λijkeijk)
log(λijk) = ϕi + αj + βk
where ϕi is an individual effect included to ensure that the fitted individual totals equal the observed
values. Since there are sometimes large numbers of individuals included in a study and the ϕi are
nuisance parameters, it is convenient to fit this as a conditional fixed effects Poisson regression
model, with the ϕi as a group variable which is not estimated explicitly [8].
Data are more readily assembled listing one line per event, including the start and end of the
observation period, exposure and event dates and an individual identifier. Example files that take
data in this format, reformat it as necessary and fit the model are available for STATA, SAS, R,
GLIM and GenStat from the self-controlled case series website at http://statistics.open.ac.uk/sccs/.
The relative incidences (RI) and 95% confidence intervals (CI) for each of the three post MMR
risk periods for our MMR and ITP example are shown in Table 1.
Table 1: Case series analysis of MMR vaccine and ITP.
risk period (days after MMR) no. of events RI (95% CI)
0-14 2 1.31 (0.30, 5.73)
15-28 8 5.95 (2.52, 14.07)
29-42 3 2.60 (0.75, 9.07)
0-42 13 3.23 (1.53, 6.79)
There is a significant increase in the risk of ITP 15-28 days after receipt of the MMR vaccine.
2.4 Advantages and assumptions
The case series method has several advantages. It requires only cases, which reduces the effort and
cost of data collection. Perhaps the most attractive feature of the case series method is that it is
self-controlled; it implicitly adjusts for all confounders that remain fixed over the observation period,
such as genetic and socio-economic factors. Time varying confounders such as age and season can
be allowed for in the baseline incidence. Another advantage is that, in some circumstances, the
self-controlled case series method has high efficiency relative to the cohort method (see section 3.2).
However, the case series method requires the following three key assumptions to be applicable.
Assumption 1: Events arise in a non-homogeneous Poisson process.
In general the self-controlled case series method is suitable for independent recurrent events. It may
also be applied to rare non-recurrent events. In this case, λijk in equation (1) is a hazard function
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representing the incidence in individuals who have not experienced the event, rather than a Poisson
rate. However the log likelihood (2) is valid in the limit φi → −∞. This is because recurrent and
non-recurrent events effectively become indistinguishable except in very large samples. Thus rare
non-recurrent events may be analysed using the case series model. For more details see Farrington
and Whitaker [5].
If recurrent events are not independent yet the occurrence of a first event is rare, then the
method can be applied using just the first event. For example in our MMR and ITP data, 5
children had 2, and 1 child had 5 hospital admissions for ITP. It is very likely that these admissions
were not independent, and the analysis should exclude any subsequent admissions after the first.
The results of this analysis are given in table 2.
Table 2: MMR vaccine and ITP: first event only.
risk period (days after MMR) no. of 1st events RI (95% CI)
0-14 2 1.59 (0.36, 7.15)
15-28 8 7.19 (2.92, 17.73)
29-42 3 3.22 (0.89, 11.59)
0-42 13 3.94 (1.78, 8.72)
There is a significant 7-fold increase in risk of ITP 15-28 days after MMR inoculation. The
increase in risk is greater than that for the analysis including all events (given in table 1) suggesting
that the relative incidences were biased toward the null.
Assumption 2: The occurrence of an event must not alter the probability of subsequent
exposure.
The exposure is assumed to be an external time-varying covariate, so that the exposure distribution
after time t is independent of the event history prior to t. This is probably the most restrictive
assumption of the self-controlled case series method. There are currently two modifications of the
method which can be used in some circumstances to correct for event-dependent exposures. Both
approaches may be used if the risk periods are not indefinite. The first approach may be used
provided individuals receive at most a single exposure, as in the case of single dose vaccines. The
observation period is redefined as starting with the age at exposure, while the end of observation
is as before. Only individuals who were exposed prior to the event are included in the analysis.
The disadvantage of this approach is that cases with events prior to exposure and unexposed cases
are excluded from the analysis, reducing study power. The second approach may be used when
individuals experience multiple exposures (as with multiple dose vaccines). In this approach, post-
event exposures are ignored and the data are analysed using methods for censoring events, described
in section 5.
It is sometimes possible to test whether exposures are event-dependent. This is done by including
a pre-exposure ‘risk’ period, which we shall call a pre-risk period, and testing whether the relative
incidence associated with this additional pre-risk period is significantly different from unity. Such
a situation arises in our motivating example: individuals with ITP would not receive the MMR
vaccine until they have fully recovered. It follows that there would be fewer cases in the period
just before exposure, which can be allowed for by including a pre-risk period. Not allowing for
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this period of low incidence would inflate the relative incidences in the post exposure risk periods
(conversely if exposure is more likely for a period after the event, the relative incidence would be
biased toward the null). The typical duration of ITP in children is 2-4 weeks. Including a 28-day
pre-risk period gives the results in table 3 (this analysis uses only first events so should be compared
with the results in Table 2).
Table 3: MMR vaccine and ITP: case series analysis with pre-risk period
risk period (days after MMR) RI (95% CI)
0-14 1.28 (0.28, 5.85)
15-28 5.84 (2.32, 14.73)
29-42 2.63 (0.72, 9.61)
0-42 3.20 (1.41, 7.26)
There were no events in the pre-risk period, thus no-one was vaccinated in the 28-day period
after the onset of ITP; in this data set the first post-event vaccine dose was 46 days after hospital
admission for ITP. Comparing these results with results with those of table 2, there is weak evidence
that the relative incidence was inflated when the short term dependence between event and exposure
was not taken into account. This method of testing for event-dependent exposures is studied further
in Farrington and Whitaker [5].
Assumption 3: The occurrence of the event of interest must not censor or affect the
observation period.
Each individual’s observation period is usually defined implicitly by combination of calendar time
and age limits, but must be independent of the event date.
This assumption may be violated when the event of interest is likely to increase the short-term
death rate. A case series method has been developed to deal with the situation where the observation
period is completely censored after the event: this will be described in section 5. The impact of
event-dependent observation periods on case series estimates remains a topic for further research.
Case series studies where the event is likely to result in death have been carried out, such as the
study by Smeeth et al. on the association between acute infection or vaccination and myocardial
infarction [9]. A simulation study showed that in this study’s case, the bias was negligible [5].
2.5 Designing a case series study
A case series design is typically used to study temporal associations for which effect of exposure
is confined to a finite risk period, after which the risk returns to the baseline level. Indefinite risk
periods can sometimes be used provided there are sufficient unexposed cases, though this results
in a loss of efficiency (see subsection 3.2 on relative efficiency and subsection 7.1 on indefinite risk
periods). Thus self-controlled case series analyses are best suited to studies on the association
between a transient exposure and an acute event, though any event for which it is possible to assign
a date of onset, such as date of hospital admission or diagnosis, should be suitable for study.
Event data may come from databases such as hospital admissions or GP data, and exposure
histories should be documented using a data source independent of event dates. In particular,
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spontaneous reporting systems for adverse drug reactions are inappropriate sources of data for the
case series method, since reporting is strongly dependent on the time interval between exposure
and the event.
Data are usually collected during a predefined study period given in terms of calendar time
and possibly age boundaries, typically determined by the availability of database records. These
boundaries are usually used to assign an observation period to each case. Typically observation
periods may vary between cases. It is advisable to select the study period so as to maximize the
chance of exposure. For example, in the study of ITP and MMR, the study period was the second
year of life, which corresponds to the age range in which children are most likely to receive primary
MMR vaccination. Once observation periods are set in place age groups can be chosen to capture
the change in incidence of the event of interest with increasing age (but see section 4). If there are
other potential temporal confounders these also need to be allowed for. For example if the event
rate varies with season, this could be allowed for using a calendar month effect or a 4 level factor
for season.
The risk periods should be chosen a priori. In reality experts often find it difficult to judge
how long a potential temporal association between exposure and event may last for, and it may be
sensible to choose a small number of contiguous risk periods for each exposure and later combine
periods where the relative incidence appears to be similar. Note that if a true association exists
and the risk periods do not include the full period for which the temporal association lasts, the
relative incidences will be biased toward the null.
Some individuals may experience repeat exposures, for example repeat prescriptions of a drug.
If the risk is expected to be the same after each exposure, risk periods after each repeat exposure
can be assigned the same factor levels. If the risk is expected to differ each time, different factor
levels should apply after each exposure in order to test for a dose effect. See Whitaker et al. [8] for
a full discussion of case series studies with multiple risk periods and repeat exposures.
2.6 Sample size
The following formula can be used to calculate the number of events n required to detect an
association of relative incidence eβ with power γ and significance level α. This formula ignores any
age effects, and assumes that all individuals have observation periods of the same length.
A = 2
p(eβr + 1− r)
1 + pr(eβ − 1)
[
β
(
eβr
eβr + 1− r
)
− log(eβr + 1− r)
]
B =
β2
A
[
p(eβr + 1− r)
1 + pr(eβ − 1)
] [
eβr(1− r)
(eβr + 1− r)2
]
n =
(
z1−α/2 + zγ
√
B
)2
A
where r is the length of the risk period divided by the length of the observation period and p is
the proportion of the population that are exposed at some time during their observation period.
Note that the formula calculates the number of events n and not the number of individuals. In
fact, events are assumed independent and two events within one individual contribute the same as
two individuals with one event. Further details and sample size formulae that take into account
age effects can be found in Musonda et al. [10].
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3 Comparison with cohort and case-control methods
The examples in section 3.1 compare the results obtained with the case series method with those
obtained from cohort and case-control studies. Examples 1 and 2 show the benefit of using the
case series method over a full cohort study in reducing the data collection effort and dealing with
incomplete information on confounders. Examples 2 and 3 show the advantage of the case series
method in controlling for selection and indication bias compared with a case-control study. In
section 3.2 the relative efficiency of the three approaches is studied in a simple case. We do not
make any comparison with other case-only designs such as the case-crossover method [11], which
is a special case of the case-control method. Farrington [12] provides an overall review of case-only
methods.
3.1 Comparative study examples
Example 1: Febrile convulsions and MMR vaccine
Barlow et al. [13] investigated the association between MMR vaccine and febrile seizures using a
large cohort of 679942 children under seven years old, living in the US. The cohort included 716
cases. The relative risk of first febrile seizure in the second week after MMR vaccine (8− 14 days)
was 2.83, with 95% CI (1.44, 5.55). A similar investigation undertaken by Farrington et al. [14]
using a case series study of 952 cases aged 12− 23 months living in England showed that the MMR
vaccine was associated with febrile convulsions with a relative incidence of 3.04, 95% CI (2.27, 4.07).
The case series study thus gave an estimate of relative incidence close to the value obtained from
the full cohort study, but with a narrower confidence interval. When the exposure risk period
is short in comparison to the observation period as in this example, the case series analysis has
good efficiency relative to a cohort study. In this instance, the case series method produces greater
precision largely because the cohort study, though very large, included fewer events than the case
series study.
Example 2: Asthma and influenza vaccine
Kramarz et al. [15] used data from a cohort of 70753 asthmatic children aged 1 − 6 years during
the 1995− 1996 asthma season living on the West Coast of the US to determine whether influenza
vaccination precipitates asthma exacerbations. The crude rate ratio of asthma exacerbation within
two weeks after influenza vaccination was 3.29, 95% CI (2.55, 4.15), which decreased after adjust-
ment for sex, age, calendar time, indicators of asthma severity and preventive care practices to 1.39,
95% CI (1.08, 1.77). A case series analysis was undertaken in the 2075 children within the cohort
who had at least one asthma exacerbation during the influenza season. The relative incidence of
asthma exacerbation within the 2 weeks after influenza vaccination was found to be 0.98, 95% CI
(0.76, 1.27). One interpretation is that the case series method controls fully for indication bias
associated with the confounding effect of underlying asthma severity, as children with more severe
conditions are the most likely to receive the vaccine. In the cohort analysis, only partial control of
such confounding may have been achieved by adjusting on proxy indicators of severity.
Example 3: Hip fracture and tricyclic antidepressants
Hubbard et al. [4] performed case-control and case series analyses to investigate the association
between tricyclic antidepressant drugs and the risk of hip fracture. The data set included 16341
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cases of hip fracture and 29889 controls drawn from the United Kingdom General Practice Research
Database (GPRD). The odds ratio for fracture within the 15 days following a prescription of tricyclic
antidepressants was 4.76, 95% CI (3.06, 7.41), whereas the equivalent relative incidence obtained
from the case series analysis was 2.30, 95% CI (1.82, 2.90). Both study designs show a positive
association between tricyclic antidepressants and hip fracture during the first 15 days of treatment,
though the strength of association from the case control study is double that from the case series
study. It is thought that the estimates gained from the case series approach may be more accurate
because the problems of selection and indication bias in the case-control study are removed. It is
also possible that the case series result could be biased toward the null, say if individuals are more
likely to take antidepressants after fracturing a hip.
These examples show how useful it can be to use more than one study design, and indeed when
suitable data arise we recommend doing a case series analysis as well as a cohort or case-control
analysis. If estimates obtained from both study designs agree this strengthens the findings. If
results do not agree it can throw light on the sources of bias.
3.2 Relative efficiency
In this subsection an expression is presented for the relative asymptotic efficiency of the case series
design, relative to an unmatched case-control design with C controls per case, for estimating the
log relative incidence β for an uncommon event in a simple scenario. Provided that the underlying
incidence is very small, the log odds ratio coincides with β, and so it makes sense to compare
asymptotic variances.
In the scenario we consider, the underlying population comprises T individuals followed up over
the same period. Of these individuals, a proportion p experience a risk period of length e1 and a
control period of length e0, while the remainder experience only a control period, of length e0+ e1.
The ratio of the risk period to the observation period is r = e1/(e0+ e1). There are n cases. In the
case-control study, a case with onset at time t is considered exposed if exposure occurred within
(t− e1, t]; for the controls a randomly selected interval of length e1 is used to determine exposure.
As shown in the Appendix, asymptotically as T →∞ (and hence n→∞), the relative efficiency
of the case series method compared with the case-control method with C controls per case is:
REC =
1− r
C (1− pr) .
eβ + C
(
eβpr + 1− pr)2
(eβpr + 1− pr) . (eβr + 1− r) .
Note that as the number of controls per case increases, the relative efficiency tends to
RE∞ =
1− r
1− pr .
eβpr + 1− pr
eβr + 1− r
which, as expected, coincides with the relative efficiency of the case series method compared to the
cohort method in this simple scenario [1] [5].
Figures 2(a) to (d) show the relative efficiency for β = log(2) and β = log(10), and for exposure
prevalences p = 0.4 and p = 0.8. The case series method is more efficient than the case-control
method with C controls per case when r is small, this efficiency advantage reducing as r increases,
p declines and β increases. When p < 1, then as the number of controls per case increases, the
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case-control method eventually becomes more efficient than the case series method, equi-efficiency
occurring when
C =
1− r
r (1− p) (eβpr + 1− pr) .
The case series method is less efficient than the cohort method except when p = 1, though the loss
in efficiency is small when r is low and p is high. A more general discussion of the relative efficiency
of the case series method relative to the cohort method may be found in Farrington & Whitaker
[5], though the qualitative findings from the simple scenario presented here hold more generally as
well.
Figure 2: Asymptotic relative efficiency (a) RI = 2, p = 0.8, (b) RI = 10, p = 0.8, (c) RI = 2,
p = 0.4, (d) RI = 10, p = 0.4. In each panel the four lines (from top to bottom) are for C = 1, 2, 4
and ∞ controls per case.
4 Semiparametric case series approach
In the parametric case series model described in Section 2, the age effect is assumed to be constant
in pre-determined age groups and the age-specific relative incidence is then approximatively repre-
sented by a step function with steps exp(αj) in the jth age group. However, mis-specification of the
age groups can produce biased estimates of β. These considerations motivated the development of
a semi-parametric model in which the age effect is left unspecified. In this model, the cumulative
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baseline relative incidence is modelled by a step function with jumps exp(αr) at the distinct event
times tr. The contribution to the semi-parametric case series likelihood of a case i who experienced
ni events is:
Li(β) =
ni∏
j=1
exp [αij + βxi(tij)]∑
r exp [αr + βxi(tr)]
where tij is the jth event time of case i, xi(t) is the exposure at time t for case i, and αij is the
value αr corresponding to tij .
An additional benefit of the semiparametric model is that it implicitly controls for exponential
time trends: these are confounded with the age effects but do not influence the exposure effects.
Example: MMR vaccine and bleeding disorders
Using the MMR and ITP data for only the first event and including a 28-day pre-exposure period,
the semiparametric model yields the relative incidences given in table 4.
Table 4: MMR vaccine and ITP: semiparametric case series model.
risk period (days after MMR) RI (95% CI)
0-14 1.34 (0.28, 6.41)
15-28 5.61 (1.97, 15.97)
29-42 2.06 (0.51, 8.24).
0-42 2.90 (1.20, 7.03)
The results are comparable to those in table 3 obtained using the parametric model with 6 age
groups.
Example: Hepatitis B vaccination and multiple sclerosis
The hypothesis that hepatitis B vaccination is a risk factor for multiple sclerosis has been discussed
at length. Data from a case-control study in France in 1998 were re-analysed using the case
series method [16] [17]. Both the event and vaccination were age dependent, and hence age was
a potential confounder if not fully allowed for in the model. The relative incidence for the 0 − 60
day post vaccination risk period using a case series model with no age effect was 2.11 with 95%
confidence interval (1.06, 4.20), this became 2.00 (0.96, 4.18) using a parametric model with 48 1-
year age classes, and dropped to 1.68 (0.77, 3.68) using the semiparametric model. Clearly, there is
substantial confounding by age which was reduced, but not eliminated, by using 48 age groups. The
semiparametric model provided the most reliable estimates in this context, as no prior assumptions
were made about the age effect.
5 Self-controlled case series approach for censoring events
Key assumptions of the self-controlled case series method are that the exposure distribution within
the observation period, and the observation period itself must be independent of prior event times.
These requirements inhibit the use of the case series method for censoring events, that is, events
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whose occurrence censors subsequent exposures. For example, if the exposure of interest is an
intervention which is contra-indicated after occurrence of the event, no exposures can occur after
the event, but the individual remains under observation. The most extreme example of a censoring
event is death whose occurrence censors the entire post-event exposure history.
5.1 Unique exposures
If the event of interest is of the censoring type, the use of the multinomial likelihood (3) obtained by
conditioning on the total number of events and exposure history is not valid since censoring events
give rise to missing exposure data. Suppose the boundaries ai, bi define the observation period that
would have applied had no censoring occurred, and suppose to begin with that all cases experience
only one exposure. We proceed by including only exposed cases in the analysis and redefine the
observation period for each individual i exposed once at age ci, to be (ci, bi] rather than (ai, bi], see
Figure 3. Indeed, if there is a unique exposure occurring at age ci, the subsequent exposure history
is always known within (ci, bi], since no further exposures occur. Thus, the case series likelihood
(3) is valid and the relative incidence can be estimated at the cost of ignoring unexposed cases.
Figure 3: configuration for one exposure
Example: Bupropion and sudden death
Bupropion is an effective smoking cessation therapy but its use in the UK has been limited by
concerns that it may increase the risk of sudden death. Data for 9329 individuals who had been
prescribed Bupropion were analysed using the self-controlled case series method to estimate the
relative incidences of seizures and death during the first 28 days of treatment [19]. The relative
incidence of seizures during the first 28 days of treatment, using a standard case series analysis,
was 3.62 with 95% CI (0.87, 15.09). As sudden death censors Bupropion therapy, we applied the
case series approach for censoring events described in Section 5.1, by defining the individual’s
observation period to start with the age Bupropion treatment was first started, and to end with age
on 11 November 2003. A total of 121 cases of sudden death were included in the analysis, including
2 in the risk period 0-27 days after the start of treatment. The relative incidence was 0.50, 95% CI
(0.12, 2.05). These results shows that Bupropion use is probably associated with an increased risk
of seizures, but no evidence was found to suggest that the drug is associated with an increased risk
of sudden death [18].
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5.2 Two or more exposures
In the case of a single exposure and ignoring any age effect, the case series log likelihood contribution
of individual i is
li(β) =
{
ni2β − (ni1 + ni2) log
(
eβei2 + ei3
)
if ni1 = 0,
1 if ni1 = 1
and the elementary score function for β is given by:
U (β) = ni2 − (ni2 + ni3) ei2e
β
ei2eβ + ei3
where nid and eid represent the number of events during, and length of interval d; d = 1 during
the pre-exposure control period prior to exposure, d = 2 during the exposure risk period and d = 3
during the post-risk control period as shown in figure 3.
Now consider the case where each individual i is exposed up to two times at ages ci1 and ci2,
with ci1 ≤ ci2. Let β1 and β2 denote the log relative incidences associated with each of the two
exposure risk periods (k = 1 and d = 2, k = 2 and d = 4), as shown in Figure 4 (note the new
d illustrated in the figure). Inference about β2 can be made using the method described for single
exposures, by using the case series likelihood restricted to cases with events in (ci2, bi]. This yields
the following score function
U1i (β2) = ni4 − (ni4 + ni5)
eβ2ei4
eβ2ei4 + ei5
.
To make inference about β1, only cases arising in (ci1, bi] are used. We proceed as if no individual
can be exposed a second time at some possibly unobserved age ci2, and denote n∗i4 the number of
events that would have arisen in the new control period that now replaces the second risk period
(k = 2 and d = 4). If n∗i4 were observed, the method for single exposures could be used, applied
to cases with events after the first exposure at age ci1. This would then yield the elementary score
function
U2i (β1) = ni2 − (ni2 + ni3 + n∗i4 + ni5)
eβ1ei2
eβ1ei2 + ei3 + ei4 + ei5
.
However, n∗i4 is not observed so this score function cannot be evaluated. We therefore replace n
∗
i4
by an unbiased estimator of n∗i4, namely the Horvitz-Thompson-like estimator ni4e
−β2 .
In the general case with more than two exposures and including age groups, the estimating
equations and sandwich variance estimators are given in Farrington et al. [18]. In such settings,
writing down and solving the estimating equations, and deriving the sandwich variance estimator,
becomes extremely cumbersome, and is impractical. An alternative approach more convenient
for computation is based on a pseudo-likelihood method. Estimates are obtained by an iterative
procedure, in which at each iteration the missing data n∗ijk are replaced by their Horvitz-Thompson-
like expected values. The pseudo-likelihood method provides a simple way of obtaining parameter
estimates using standard Poisson regression software. It also can be exploited to obtain bootstrap
standard errors and interval estimates [18].
Example: Oral polio vaccine and intussusception
Intussusception is a condition where the bowel folds in on itself causing an obstruction. Most
children diagnosed with intussusception have an operation and recover completely, so normally this
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Figure 4: Configuration for two exposures.
is not a censoring event. The data are 456 first hospital admissions for intussusception of children
up to age 2 years, collected between 2002 and 2005 in 11 Latin American countries. The vaccination
history of each case was collected through an interview with the child’s parents at the time of the
child’s treatment. There was no follow up, so the subsequent vaccination history was censored. The
children received up to 5 doses of the oral polio vaccine (OPV). A single risk period 0 − 30 days
after each OPV dose is used, giving 5 risk periods. We used 15 one or three month age groups [18].
Relative incidences and 95% percentile bootstrap confidence intervals are given in Table 5.
Table 5: Censoring event case series analysis of OPV vaccine and intussusception.
risk period 0-30 days after dose: RI (95% CI)
1 1.25 (0.63, 2.24)
2 1.07 (0.74, 1.53)
3 0.97 (0.68, 1.37)
4 1.00 (0.50, 1.62)
5 1.60 (0.00, 6.13)
any dose 1.05 (0.82, 1.34)
No significant change in incidence of intussusception in the 30-day period after vaccination with
OPV relative to the control periods was found.
6 Sequential approach for pharmacovigilance
6.1 The case series SPRT
The case series method is rapid, easy to apply and avoids confounding, this recommends it for
use in pharmacovigilance, as well as pharmacoepidemiology. A sequential case series method has
been developed for prospectively monitoring the safety of a new drug or a new vaccine by formally
testing the null hypothesis of absence of new drug or vaccine effect H0 : eβ = 1, where eβ is the
relative incidence, versus the alternative hypothesis H1 : eβ = eβA where eβA is the alternative
hypothesis relative incidence value that we wish to detect (eβA > 1). To perform this test, a risk-
adjusted sequential probability ratio test (SPRT) can be used [20]. This test is applied at the end
of successive surveillance intervals, a calendar time period of set length.
14
At the sth surveillance interval, the age effect is profiled out by maximizing the log likelihood
under H1 and under H0 (simulations have shown that using profile likelihoods in this way has little
bearing on the results) [20]. The logarithm of the case series profile likelihood ratio test statistic Λs
is calculated, and the value of the sequential test statistic Zk corresponding to the running total is
obtained as follows:
Zs = Zs−1 + Λs, and Z0 = 0.
The value of Zs is compared to pre-determined test boundaries log(A) and log(B), conventionally
specified in terms of nominal error probabilities α∗ and β∗, with A = β∗(1 − α∗)−1 and B =
(1− β∗)α∗−1.
If log(A) ≤ Zs ≤ log(B), then no decision is made and the procedure is repeated at step s+ 1,
otherwise, the sequential test terminates at step s. In this case, if Zs > log(B) then the alternative
hypothesis H1 is accepted and if Zs < log(A) then the null hypothesis H0 is accepted.
Example: influenza vaccine and Bell’s Palsy
After the introduction of an inactivated nasal formulation of the influenza vaccine in Switzerland
in October 2000, an increased number of Bell’s palsy, an acute facial paralysis affecting the 7th
facial nerve were reported. Using the case series method, the relative incidence within the 31− 60
day post-vaccination risk period was estimated to be 35.6, 95% CI (14.1− 89.8) [21]. A case series
analysis was performed using a total of 2263 episodes of Bell’s palsy in the UK after the standard
influenza vaccine, recorded in the General Practice Research Database from July 1st, 1992 to 30th
June 2005. A non significant relative incidence of Bell’s palsy in the 3 months following parenteral
inactivated influenza vaccine was found, RI 0.92, 95% CI (0.78− 1.08).
We reanalysed these UK data using the case series SPRT, as if they were collected prospectively.
We used a six month surveillance interval, 1−60 day risk period after any dose of influenza vaccine,
for two values of the alternative hypothesis relative incidence eβA = 1.5 and 5. In view of possible
temporal confounding from the highly seasonal administration of influenza vaccine, the analysis
was performed using a parametric case series model with 12 one month calendar time periods.
Figure 5(a) shows that the null hypothesis is accepted at the end of the 3rd surveillance interval,
that is, after 18 months (for either α∗ = β∗ = 0.001 or α∗ = β∗ = 0.01). Figure 4(b) shows that
if the alternative hypothesis relative incidence is eβA = 1.5, then the issue remains undecided after
12 years, or 10.5 years if the upper boundaries correspond to α∗ = β∗ = 0.001 or α∗ = β∗ = 0.01,
respectively. Thus the case series SPRT is sensitive to the choice of eβA .
6.2 Some recommendations
The case series SPRT is applicable primarily when risk periods are short. A surveillance interval of
6 months is recommended for use, except when events are so rare that there is an appreciable proba-
bility of no cases arising within a 6-month period, in which case we suggest using 1-year surveillance
intervals. For most vaccination programmes, it is essential to control for age effects or, occasionally,
for seasonal effects as in the example on influenza vaccine and Bell’s palsy. We recommend that
this is done by pre-selecting age groups (or seasonal intervals) in which the effect can reasonably
be assumed constant, and using profile likelihoods to eliminate the nuisance parameters. Failing to
allow for age and temporal effects may produce erroneous results. See Hocine et al. [17] for further
details.
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Figure 5: SPRT for 1 - 60 day risk period using Influenza and Bell’s Palsy data. Lower boundary
−4.6(α∗ = β∗ = 0.01); upper boundary not shown. (a) eβA = 5; (b) eβA = 1.5.
The SPRT is ideal for monitoring a new drug. A related approach, using the CUSUM, can
be used for long-term monitoring of one or more established vaccines assumed to be safe. Indeed,
the CUSUM never results in acceptance of the null hypothesis and in this sense is well-suited for
long-term monitoring. The aim of such monitoring could be to identify problems resulting from
changes in drug production or delivery over time.
7 Some further extensions
7.1 Long and indefinite risk periods
The case series method is most efficient when the risk periods are short in comparison to the
observation period. However, it is possible to apply the case series method to non-acute events
using long or indefinite risk periods. If risk periods are indefinite this is only recommended if there
are some unexposed cases, since age and exposure risk effects may otherwise be confounded with
each other. Simulations have shown that relatively few unexposed cases are required to avoid serious
confounding with age [6]. The inclusion of unexposed cases is also advisable in studies using long
risk periods. We also recommend using the semi-parametric model for such analyses.
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Example: MMR vaccine and autism
In the original case series analyses of the association between MMR vaccine and autism, risk of
autism diagnosis within 0.5, 1 and 2 years of MMR vaccination were studied; no significant as-
sociation was found [3]. In a later reanalysis incidence of autism diagnosis both within 5 years
and any time after the vaccine was also considered [22]. An appreciable number of autism cases
were unvaccinated. The relative incidence of autism diagnosis at any time after MMR vaccination
was 1.06, with 95% confidence interval (0.49, 2.30), again, there was no evidence to support an
association. The indefinite risk period reanalysis was later performed using the semi-parametric
model, which is advisable here. This yielded a slightly lower relative incidence of 0.88, with 95%
confidence interval (0.40, 1.95) [5].
7.2 Bivariate counts
In a case series study in which two types of event R and S may occur, the effect of an intermittent
exposure on the occurrence of R rather than S, may be evaluated by a conditional relative incidence
denoted RRC . The RRC is defined as the ratio between RRR and RRS , the relative risks of R and
S, respectively, and is estimated by the ratio of their estimates obtained separately by maximizing
the appropriate likelihood (3). The variance of the RRC estimate is simply the sum of the variances
of the estimates of RRR and RRS under the assumption of independence of the counts of R and S
[23]. A test for checking such an assumption was proposed by Hocine et al. [24]. The test statistic
was derived from a conditional likelihood using a bivariate Poisson-generated multinomial model.
Robust estimation is described in Hocine et al [25].
8 Future developments
This paper gives a general overview of the self-controlled case series method and its extensions
available to date. The method is still under development and future work includes looking at
replacing risk periods with smooth functions of risk. We also hope to investigate the independence
of multiple events and the extent of any bias introduced when the observation period depends on
the event of interest.
References
[1] Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation.
Biometrics 1995; 51: 228-35.
[2] Farrington CP, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M and Miller
E. A new method for active surveillance of adverse events from diphtheria tetanus pertussis
and measles mumps rubella vaccines. Lancet 1995; 345: 567-569.
[3] Taylor B, Miller E, Farrington CP, Petropoulos M-C, Favot-Mayaud I, Li J, Waight PA. Autism
and measles, mumps and rubella vaccine: no epidemiological evidence for a causal association.
Lancet 1999; 353: 2026-2029.
17
[4] Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to Tricyclic and selec-
tive serotonin reuptake inhibitor antidepressants and the risk of hip fracture. American Journal
of Epidemiology 2003; 158: 77-84.
[5] Farrington CP, Whitaker HJ. Semiparametric analysis of case series data (with discussion).
Applied Statistics 2006; 55: 553-94.
[6] Musonda P, Hocine MN, Whitaker HJ and Farrington CP. Self-controlled case series analyses:
small sample performance. Computational Statistics and Data Analysis 2007; in press.
[7] Miller E, Waight P, Farrington P, Andrews N, Stowe J and Taylor B. Idiopathic thrombocy-
topenic purpura and MMR vaccine. Archives of disease in childhood 2001; 84: 227-229.
[8] Whitaker HJ, Farrington CP, Spiessens B and Musonda P. Tutorial in biostatistics: The self-
controlled case series method. Statistics in Medicine 2006; 25: 1768-97.
[9] Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P and Vallance P. Risk of myocardial
infarction and stroke after acute infection or vaccination. New England Journal of Medicine
2004; 351: 2611-2618.
[10] Musonda P, Farrington CP, Whitaker HJ. Sample sizes for self-controlled case series studies.
Statistics in Medicine 2006; 25: 2618-2631.
[11] Maclure M. The case-crossover design: a method for studying transient effects on the risk of
acute events. American Journal of Epidemiology 1991; 133: 144-153.
[12] Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only
methods. Vaccine 2006; 22: 2064-2070.
[13] Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, Black SB,
Shinefield HR, Ward JI, Marcy SM, DeStefano F, Chen RT, for the Centers for Disease Control
and Prevention Vaccine Safety Datalink Working Group. The risk of seizures after receipt of
whole-cell pertussis or measles, mumps, and rubella vaccine. The New England Journal of
Medicine 2001; 345: 656-61.
[14] Farrington CP, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M and Miller
E. A new method for active surveillance of adverse events from diphtheria tetanus pertussis
and measles mumps rubella vaccines. Lancet 1995; 345: 567-569.
[15] Kramarz P, DeStefano F, Gargiullo PM, Davis RL, Chen RT, Mullooly JP, Black SB, Shinefield
HR, Bohlke K, Ward JI, Marcy SM, for the Vaccine Safety Datalink Team. Archives of Family
Medicine 2000; 9: 617-23.
[16] Touze´ E, Fourrier A, Rue-Fenouche C, Rende-Oustau V, Jeantaud I, Begaud B, et al. HB
vaccination and first central nervous system demyelinating event: a case-control study. Neu-
roepidemiology 2002; 21: 180-6.
[17] Hocine MN, Farrington CP, Touze´ E, Whitaker HJ, Fourrier A, Moreau T, Tubert-Bitter P.
Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of
a case-control study using the self-controlled case series method. Vaccine 2007; 25: 5938-43.
18
[18] Farrington CP, Whitaker HJ and Hocine MN. Case series analy-
ses of censoring events. Technical report 2006; 06/12. (available from
http://statistics.open.ac.uk/TechnicalReports/TechnicalReportsIntro.htm)
[19] Hubbard R, Lewis S, West J, Smith C, Godfrey C, Smeeth L, Farrington P and Britton J.
Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health
Improvement Network. Thorax 2005; 60: 848-850.
[20] Hocine MN, Musonda P, Andrews NJ and Farrington CP. Sequential case
series for pharmacovigilance. Technical report 2007; 07/07. (available from
http://statistics.open.ac.uk/TechnicalReports/TechnicalReportsIntro.htm)
[21] Stowe J, Andrews N, Wise L and Miller E. Bell’s palsy after parenteral inactivated influenza
vaccine. Human Vaccines 2006; 2: 110-112.
[22] Farrington CP, Miller E and Taylor B. MMR and autism: further evidence against a causal
association. Vaccine 2001; 19: 3632-3635.
[23] Hocine M, Tubert-Bitter P, Moreau T, Chavance M, Varon E, Guillemot D. A relative risks ra-
tio between antibiotic use and recurrent bacteria colonization in cohort and case-series studies.
Journal of Clinical Epidemiology 2007; 60: 361-365.
[24] Hocine M, Guillemot D, Tubert-Bitter P and Moreau T. Testing independence between two
Poisson-generated multinomial variables in case-series and cohort studies. Statistics in Medicine
2005; 24: 4035-4044.
[25] Hocine M, Moreau T and Chavance M (2006). Discussion on the paper by Farrington and
Whitaker. Applied Statistics 2006; 55: 585-586.
Appendix
This Appendix provides some details of the calculation of the relative efficiency of the case series
method relative to the case-control method for rare events. The scenario considered is as described
in the main text.
Suppose that n events arise in the T individuals in the underlying population, including m
events among individuals who experience the exposure. Of these m events, suppose that m0 arise
in the control period and m1 in the risk period. The case series log-likelihood is:
lcs = m0 log
e0
e0 + e1eβ
+m1 log
e1e
β
e0 + e1eβ
,
and the asymptotic variance of the log relative incidence β̂ in the case series design is given by:
varcs(β̂) =
1
m
(
eβr + 1− r)2
eβr(1− r) .
If eφ denotes the baseline incidence in the absence of exposure, then
E(m) = Teφp(e1eβ + e0).
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Now consider an unmatched case-control study based on the n cases arising in the same popu-
lation as described above, and with N = Cn controls sampled from the non-cases. We assume that
the underlying incidence exp(φ) is very small, so β is approximately equal to the log odds ratio.
The case-control log likelihood is:
lcc = nψ + n1β − (n1 +N1) log
(
1 + eψ+β
)− (n0 +N0) log (1 + eψ)
where n1 and n0 are the number of exposed and unexposed cases, respectively, and N1 and N0
are the number of exposed and unexposed controls, respectively, and ψ is an additional parameter
that depends on the sampling proportions. Letting pi denote the expected proportion of exposed
controls,
exp(−ψ) = C(eβpi + 1− pi).
Since the event is rare, the expected proportion of exposed controls is approximately pi = pr. It
follows that the asymptotic case-control variance of β̂ for rare events is given by:
varcc
(
β̂
)
=
eβ + C(eβpr + 1− pr)2
nCeβpr(1− pr) .
Furthermore,
E(n) = Teφ[p(e1eβ + e0) + (1− p)(e1 + e0)].
Hence, asymptotically as T → ∞ (and hence n → ∞), the relative efficiency of the case series
method compared with the case-control method for rare events with k controls per case is:
REC = lim
T→∞
varcc(β̂)
varcs(β̂)
=
1− r
C (1− pr) .
eβ + C
(
eβpr + 1− pr)2
(eβpr + 1− pr) . (eβr + 1− r) .
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